BYSANTI

Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for the central nervous system; Pharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical preparations for the treatment and prevention of insomnia; Pharmaceutical preparations for the treatment and prevention of social anxiety; Pharmaceutical preparations for the treatment and prevention of performance anxiety; Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations for the treatment of schizophrenia; Pharmaceutical preparations for the treatment of bipolar disorder; Pharmaceutical preparations for the treatment of Parkinson's Disease psychosis; Pharmaceutical preparations for the treatment of jet lag disorder; Pharmaceutical preparations for the treatment of atopic dermatitis; Pharmaceutical preparations for the treatment of Delayed Sleep Phase Disorder (DSPD); Pharmaceutical preparations for the treatment of Autism Spectrum Disorder (ASD); Pharmaceutical preparations for the treatment of gastroparesis; Pharmaceutical preparations for the treatment of covid-19 pneumonia; Pharmaceutical preparations for the treatment of hematologic malignancies; Pharmaceutical preparations for treating epidermal problems; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology